To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
19 Current news of Bayer HealthCarerss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Net income more than doubled to EUR 642 million (plus 125.3 percent)
The Bayer Group achieved further sales growth and significantly increased earnings in the third quarter of 2011. “It was a good quarter for Bayer,” Management Board Chairman Dr. Marijn Dekkers said Thursday at the presentation of the interim report. He described the continuing growth momentum in ...
First quarter of 2011: all subgroups lift sales and earnings
The Bayer Group got off to a successful start to 2011. “All three subgroups contributed to the strong start to the year with sales and earnings increases,” Bayer CEO Dr. Marijn Dekkers explained on Thursday when the company’s first-quarter results were released. He was especially pleased at how ...
Planned net reduction of about 2,000 jobs worldwide by the end of 2012
Bayer plans to invest its resources even more systematically in growing the company and enhancing its innovative capability. The focus will be on researching, developing and marketing new products, particularly in HealthCare and CropScience, and on expanding activities in the emerging markets. ...
Pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing
The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. “The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success,” said Werner ...
Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technology ...
Bayer HealthCare published concrete plans regarding the previously announced synergy goals. The integration of the activities of the former Schering AG, Germany, with the Pharma division of Bayer HealthCare shall result in annual savings of EUR 700 million from 2009. Adjustments to personnel ...
More than 200 staff for Marketing and Sales integrated in Russia, Belarus, the Ukraine and Kazakhstan
Bayer HealthCare has taken over the marketing and distribution network of its partner Pharmonyx Ltd. in Russia, Belarus, the Ukraine and Kazakhstan. Pharmonyx has been responsible for marketing and distributing BHC's products in these countries since 1999. Both parties have agreed to refrain from ...
U.S. Pharma Sites and Future Headquarters
Bayer HealthCare announced a structural realignment of its global pharmaceutical research and development organization. The company also outlined its future U.S. pharma site plan, and said that New Jersey will be home to its U.S. headquarters for pharmaceuticals. These moves follow Bayer's ...
Bayer HealthCare (BHC) and Topsun Science and Technology Co., Ltd. together announced that BHC's Consumer Care Division has signed an agreement in China to acquire the Western over-the-counter (OTC) cough and cold portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., ...
Following the success of Bayer's takeover offer for Schering, the two companies are confident about their common future. "We will combine two successful pharmaceutical companies to form a single, even more powerful unit and create a leading global enterprise," said Bayer Management Board Chairman ...